Statute
Directive 2001/83/EC
24 published works
HLC - All Publications
Pharmacy compounding under the EU pharma law package – What marketing authorisation holders and innovators need to know
By Cadwalader Wickersham & Taft
In 2023, the European Commission proposed the most significant reform of the EU pharmaceutical legislation in over 20 years, replacing Directive 2001/83/EC and Regulation (EC) No 726/2004. The legislative process…
EU Law Enforcement
[DRAFT] Accountability in EU pharmaceutical enforcement: the problem of many hands
By Oliwia, Kaloyan and Carolin The problem and regulatory framework Understanding who enforces medicines regulations in the EU is the real clinical trial - side effects include confusion and legal…
BioSlice Blog
An update from the European Court of Justice on discount campaigns run by mail order pharmacies
By Libby Amos-Stone, Katya Farkas, Heba Jalil
Do discount campaigns on prescription-only medicines (POMs) run by mail order pharmacies lure patients into consuming medicinal products? The European Court of Justice (CJEU) in the case of Apothekerkammer Nordrhein…
BioSlice Blog
When discount campaigns regarding prescription only medicines do not fall within the definition of advertising in the EU
By Libby Amos-Stone, Katya Farkas
Do discount campaigns on prescription-only medicines (POMs) run by mail order pharmacies lure patients into consuming medicinal products? Advocate General Szpunar has opined that they do not. The opinion comes…
Inside EU Life Sciences
European Parliament adopts its Position on EU Pharma Law Review: 8 Key Takeaways for Industry
By Peter Bogaert, Grant Castle, Robin Blaney, Marie Doyle-Rossi, Anna Wawrzyniak
On 10 April 2024, the European Parliament adopted its position on the Commission proposal to reform the core EU pharmaceutical legislation (see here and here). In doing so, the European Parliament has met…
Inside EU Life Sciences
EU Pharma Revision Series: Pharmacovigilance
By Grant Castle, Marie Doyle-Rossi, Anna Wawrzyniak, Valeria Sturla
The European Commission’s proposal to amend the current pharmaceutical regulatory framework includes a draft Directive on medicines for human use (the “Proposed Directive”) and a draft Regulation on the central…
Inside EU Life Sciences
EU Pharma Legislation Review Series: National MA Procedures Including the Mutual Recognition Procedure and Decentralized Procedure
The European Commission (the “Commission”) wants to “avoid unnecessary administrative and financial burdens for applicants and competent authorities.” As such, the Commission’s proposal for a revised Directive on the Union…
Inside EU Life Sciences
EU Pharma Legislation Review Series: Paediatric Medicines
By Peter Bogaert, Grant Castle, Marie Doyle-Rossi, Anna Wawrzyniak
More Obligations for the Same Reward? On 26 April 2023, the European Commission published its long awaited proposal to revise the EU’s general pharmaceutical legislation. As expected, the Commission’s proposal…
Inside EU Life Sciences
EU Pharma Legislation Review Series: Regulatory Data Protection
By Robin Blaney, Anna Wawrzyniak
The European Commission (“Commission”) intends to change the rules on regulatory data protection (“RDP”) of medicinal products. The Commission stated in its Impact Assessment for the revised pharmaceutical legislation that…
Inside EU Life Sciences
EU Pharma Legislation Review Series: The EU’s proposals to amend its pharmaceutical laws released today
By Grant Castle, Peter Bogaert, Marie Doyle-Rossi
This is the first in a series of Covington blogs about the EU’s proposals to amend the current pharmaceutical regulatory framework, which were released today (see here). It introduces some…